Apex Biotechnology

Apex Biotechnology FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Apex Biotechnology (1733.TW) as of Nov 22, 2026 is 91.31 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 233.62 % — a change of -60.91% (lower).

FCF Conversion

91.31 %

YoY

-60.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Apex Biotechnology is 2025 91.31 % . FCF Conversion Rate (FCF/EBITDA) of Apex Biotechnology was 2024 233.62 % . It decreases by -60.91% lower compared to the previous year.

The Apex Biotechnology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-8.12 TWD
Jan 1, 2019
356.53 TWD
Jan 1, 2020
245.03 TWD
Jan 1, 2021
75.99 TWD
Jan 1, 2022
-7.47 TWD
Jan 1, 2023
177.41 TWD
Jan 1, 2024
233.62 TWD
Jan 1, 2025
91.31 TWD
The Apex Biotechnology FCF Conversion history
YEARFCF ConversionYoY
91.31 %-60.91%
233.62 %+31.69%
177.41 %-2,474.17%
-7.47 %-109.83%
75.99 %-68.99%
245.03 %-31.27%
356.53 %-4,491.70%
-8.12 %-115.76%
51.51 %-99.37%
8,161.02 %+4,696.94%
170.13 %+130.03%
73.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apex Biotechnology Stock analysis

What does Apex Biotechnology do? Apex Biotechnology Corp is a Taiwan-based company specializing in the development of innovative biotechnology products. The company was founded in 2002 and offers a wide range of products and services to its customers. Apex Biotechnology Corp began with the production of specialty chemicals and enzymes for research and development purposes. Over the years, the company has expanded its business and focused on the development of diagnostic products, dietary supplements, and pharmaceutical products. The company's business model focuses on the development and marketing of biotechnology products. Apex Biotechnology Corp has established advanced research centers and works closely with research institutions and pharmaceutical companies worldwide to develop innovative solutions. The company operates in various sectors, including diagnostics, dietary supplements, and pharmaceuticals. It offers a diverse range of products, including enzyme immunoassays, lateral flow tests, dietary supplements, and pharmaceuticals. Apex Biotechnology Corp has built strong relationships with research institutions and pharmaceutical companies and has successfully marketed its products internationally. Apex Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apex Biotechnology stock

FCF Conversion Rate (FCF/EBITDA) of Apex Biotechnology is 91.31 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Apex Biotechnology changed from 233.62 % to 91.31 %, representing a -60.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Apex Biotechnology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Apex Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Apex Biotechnology

All Key Metrics — Apex Biotechnology